Evidence for elevated cerebrospinal fluid ERK1/2 levels in Alzheimer dementia

  • P. S
  • H. S
  • H. K
  • et al.
Citations of this article
Mendeley users who have this article in their library.


Cerebrospinal fluid (CSF) samples from 33 patients with Alzheimer dementia (AD), 21 patients with mild cognitive impairment who converted to AD during followup (MCI-AD), 25 patients with stable mild cognitive impairment (MCI-stable), and 16 nondemented subjects (ND) were analyzed with a chemiluminescence immunoassay to assess the levels of the mitogen-activated protein kinase ERK1/2 (extracellular signal-regulated kinase 1/2). The results were evaluated in relation to total Tau (tTau), phosphorylated Tau (pTau), and beta-amyloid 42 peptide (A42). CSF-ERK1/2 was significantly increased in the AD group as compared to stable MCI patients and the ND group. Western blot analysis of a pooled cerebrospinal fluid sample revealed that both isoforms, ERK1 and ERK2, and low amounts of doubly phosphorylated ERK2 were detectable. As a predictive diagnostic AD biomarker, CSF-ERK1/2 was inferior to tTau, pTau, and A42. © 2011 Philipp Spitzer et al.




P., S., H., S., H., K.-K., M., O., D., C., L., P., … H.-W., K. (2011). Evidence for elevated cerebrospinal fluid ERK1/2 levels in Alzheimer dementia. International Journal of Alzheimer’s Disease. H.-W. Klafki, Department of Psychiatry and Psychotherapy, Laboratory for Molecular Neurobiology, University of Duisburg-Essen, Virchowstrae 174, 45147 Essen, Germany. E-mail: hans.klafki@uni-due.de: Hindawi Publishing Corporation (410 Park Avenue, 15th Floor, 287 pmb, New York NY 10022, United States). Retrieved from http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed10&NEWS=N&AN=2012021771

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free